To Our Valued Seegene Customer,
The World Health Organization has identified the Omicron variant (B.1.1.529) as the latest strain of the SARS-CoV-2 virus to be designated as a Variant of Concern.
As the first cases are emerging in the US, Seegene confirms that the performance or quality of the Seegene EUA Allplex™ 2019-nCoV Assay is not impacted by either the Omicron variant or the Delta variants.
Seegene has conducted an in-silico analysis of this Variant of Concern, indicating that our assay can amplify and detect 100% of the currently available SARS-CoV-2 Omicron sequences.
For more details, read the complete Seegene statement on testing for the COVID-19 Omicron variant here:
As a leading molecular diagnostic company, Seegene continues to monitor new activity connected to COVID-19 Variants of Concern to ensure our assays’ integrity and excellent performance.
Furthermore, Seegene has developed a series of Research Use Only assays to identify some mutations consistent with Omicron, and differentiate between Omicron and other variants such as the Delta variants.
Please feel free to contact Seegene Technologies if you have any further questions.